Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 7465741, 6 pages
http://dx.doi.org/10.1155/2016/7465741
Research Article

Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients

1Laboratorio di Oncologia, Istituto Giannina Gaslini, Via Gaslini 5, 16147 Genoa, Italy
2Centro Cellule Staminali, IRCCS AOU San Martino-IST, Largo R. Benzi 10, 16132 Genoa, Italy
3UOC Oncologia, Istituto Giannina Gaslini, Via Gaslini 5, 16147 Genoa, Italy

Received 20 May 2016; Revised 4 July 2016; Accepted 19 July 2016

Academic Editor: Ban-Hock Toh

Copyright © 2016 Fabio Morandi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. R. Pinto, M. A. Applebaum, S. L. Volchenboum et al., “Advances in risk classification and treatment strategies for neuroblastoma,” Journal of Clinical Oncology, vol. 33, no. 27, pp. 3008–3017, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Morandi, M. V. Corrias, and V. Pistoia, “Evaluation of bone marrow as a metastatic site of human neuroblastoma,” Annals of the New York Academy of Sciences, vol. 1335, no. 1, pp. 23–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. K. T. Vo, K. K. Matthay, J. Neuhaus et al., “Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group project,” Journal of Clinical Oncology, vol. 32, no. 28, pp. 3169–3176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Morandi, I. Levreri, P. Bocca et al., “Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release,” Cancer Research, vol. 67, no. 13, pp. 6433–6441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Morandi, G. Cangemi, S. Barco et al., “Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients,” BioMed Research International, vol. 2013, Article ID 956878, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Morandi, P. Scaruffi, F. Gallo et al., “Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-g proteins,” PLoS ONE, vol. 7, no. 1, article e29922, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Pistoia, F. Morandi, G. Bianchi, A. Pezzolo, I. Prigione, and L. Raffaghello, “Immunosuppressive microenvironment in neuroblastoma,” Frontiers in Oncology, vol. 3, article 167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. D. T. Lau, M. D. Norris, G. M. Marshall, M. Haber, and L. J. Ashton, “HLA-G polymorphisms, genetic susceptibility, and clinical outcome in childhood neuroblastoma,” Tissue Antigens, vol. 78, no. 6, pp. 421–427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Le Bouteiller and F. Lenfant, “Antigen-presenting function(s) of the non-classical HLA-E, -F and -G class I molecules: the beginning of a story,” Research in Immunology, vol. 147, no. 5, pp. 301–313, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Pistoia, F. Morandi, X. Wang, and S. Ferrone, “Soluble HLA-G: are they clinically relevant?” Seminars in Cancer Biology, vol. 17, no. 6, pp. 469–479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Morandi and V. Pistoia, “Interactions between HLA-G and HLA-E in physiological and pathological conditions,” Frontiers in Immunology, vol. 5, article 394, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. S. L. Cohn, A. D. J. Pearson, W. B. London et al., “The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 289–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Vicente, M. Podestà, A. Pitto et al., “Progenitor cells trapped in marrow filters can reduce GvHD and transplant mortality,” Bone Marrow Transplantation, vol. 38, no. 2, pp. 111–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Morandi, C. Venturi, R. Rizzo et al., “Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation,” Journal of Neuroimmune Pharmacology, vol. 8, no. 4, pp. 944–955, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Menier, M. Rabreau, J.-C. Challier, M. Le Discorde, E. D. Carosella, and N. Rouas-Freiss, “Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis,” Blood, vol. 104, no. 10, pp. 3153–3160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Montespan, F. Deschaseaux, L. Sensébé, E. D. Carosella, and N. Rouas-Freiss, “Osteodifferentiated mesenchymal stem cells from bone marrow and adipose tissue express HLA-G and display immunomodulatory properties in Hla-mismatched settings: implications in bone repair therapy,” Journal of Immunology Research, vol. 2014, Article ID 230346, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Morandi, L. Raffaghello, G. Bianchi et al., “Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens,” Stem Cells, vol. 26, no. 5, pp. 1275–1287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Rizzo, D. Campioni, M. Stignani et al., “A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells,” Cytotherapy, vol. 10, no. 4, pp. 364–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Selmani, A. Naji, I. Zidi et al., “Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells,” Stem Cells, vol. 26, no. 1, pp. 212–222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Alsahebfosoul, A. Zavaran Hosseini, R. Salehi, M. Etemadifar, N. Esmaeil, and A. Jamshidian, “Evaluation of soluble human leukocyte antigen-G (sHLA-G) isoforms and regulatory T cells in relapsing-remitting multiple sclerosis,” Iranian Journal of Allergy, Asthma and Immunology, vol. 14, no. 3, pp. 298–305, 2015. View at Google Scholar · View at Scopus